Immunological Disorders and Immunotherapy
Open Access

Complement Cascade Regulation in Systemic Disorders: Contemporary Approaches to Targeted Therapeutic Development

Luciana Moretti^{* *}Correspondence: Luciana Moretti, Department of Clinical Immunology, Alpine Institute of Medical Sciences, Milan, Italy, Email:

Author info »

Description

The complement system is a highly coordinated network of circulating proteins and membrane-associated molecules that contributes to host defense, removal of damaged cells, and maintenance of tissue homeostasis. Although traditionally recognized for its participation in protection against bacterial and viral infections, extensive research has demonstrated that complement activity also influences inflammatory regulation, cellular communication, tissue repair, and vascular function. Under normal physiological conditions, activation of this system is tightly controlled by numerous regulatory proteins that prevent injury to healthy tissues. When these control mechanisms become disturbed, excessive complement activation may contribute to persistent inflammatory diseases involving the kidneys, skin, joints, nervous system, blood vessels, lungs, and gastrointestinal tract. Growing knowledge of complement biology has encouraged development of therapeutic strategies designed to regulate specific components of this complex network while preserving essential protective functions.

The complement cascade can be activated through three principal pathways known as the classical, lectin, and alternative pathways. Although these pathways begin through different molecular events, each converges toward activation of central complement proteins that amplify inflammatory responses and promote elimination of foreign organisms. The classical pathway is initiated primarily after recognition of antigen-antibody complexes, whereas the lectin pathway responds to carbohydrate structures located on microbial surfaces. The alternative pathway maintains continuous low-level activity that allows rapid amplification when activating signals are detected. These coordinated mechanisms provide efficient biological surveillance while remaining under strict regulatory control during normal physiological conditions.

Activation of complement proteins generates biologically active fragments that influence numerous cellular populations. Complement components C3a and C5a function as potent inflammatory mediators capable of attracting neutrophils, monocytes, and additional leukocytes toward affected tissues. These molecules also stimulate production of cytokines, increase vascular permeability, and influence endothelial cell activation. Although these responses contribute to effective elimination of infectious organisms, prolonged production of complementderived mediators may support chronic inflammation when regulatory mechanisms become less effective.

Neutrophils respond rapidly to complement activation by migrating toward inflamed tissues through chemotactic signals generated during the cascade. Once activated, these cells release proteolytic enzymes, reactive oxygen species, antimicrobial peptides, and extracellular traps that contribute to elimination of microorganisms. Persistent activation, however, may result in injury to surrounding healthy tissues. Studies involving inflammatory kidney disease, vasculitis, psoriasis, and systemic connective tissue disorders have demonstrated considerable interaction between complement activation and neutrophilmediated tissue injury.

Dendritic cells integrate complement-derived signals with antigen presentation, influencing activation of T lymphocytes and maintenance of peripheral tolerance. Complement receptors expressed on dendritic cells modify cytokine production, cellular maturation, and expression of costimulatory molecules required for lymphocyte activation. Through these mechanisms, complement proteins influence adaptive immune responses while connecting innate and adaptive defense systems. Persistent complement activation may therefore contribute to chronic inflammatory diseases by affecting both immediate inflammatory responses and long-term lymphocyte behavior.

The kidneys represent one of the organs most frequently affected by complement dysregulation. Glomerular tissues possess extensive vascular networks where circulating complement proteins interact closely with endothelial cells and filtration membranes. Persistent activation contributes to endothelial injury, inflammatory cell recruitment, and deposition of complement complexes within glomeruli. These alterations gradually impair filtration function and may contribute to chronic kidney disease if inflammatory activity remains uncontrolled.

Blood vessels are also influenced significantly by complement activation. Endothelial cells exposed to complement fragments increase expression of adhesion molecules that facilitate migration of inflammatory cells into surrounding tissues. Complement-mediated endothelial activation additionally affects coagulation pathways, vascular permeability, and smooth muscle cell behavior. These interactions contribute to vascular inflammation observed in several systemic inflammatory diseases and may increase long-term cardiovascular risk.

The intestinal microbiota also influences complement activity through interactions with epithelial barriers and circulating inflammatory mediators. Beneficial microorganisms contribute to maintenance of mucosal integrity and influence production of regulatory proteins that limit excessive complement activation. Disturbances in microbial composition may alter these protective mechanisms, increasing susceptibility to persistent intestinal and systemic inflammatory responses. Continued investigation seeks to clarify relationships between microbial communities and complement regulation across different clinical conditions.

Monoclonal antibodies directed against complement protein C5 represent one of the earliest successful examples of targeted complement inhibition. These therapies prevent formation of terminal complement complexes responsible for membrane injury while reducing generation of inflammatory mediators derived from C5 activation. Clinical use has demonstrated value in selected disorders characterized by excessive complement activity, encouraging further investigation of additional complement-directed therapies.

Conclusion

Ongoing investigations continue exploring interactions among complement proteins, inflammatory cells, vascular biology, metabolism, and tissue repair. Increasing knowledge regarding these interconnected biological systems is expected to support development of more selective therapeutic approaches capable of controlling persistent inflammation while maintaining physiological host defense. Continued collaboration between laboratory researchers and clinical investigators will remain essential for translating molecular discoveries into effective strategies that improve patient care across a wide spectrum of inflammatory disorders.